10x Genomics Key Executives

This section highlights 10x Genomics's key executives, including their titles and compensation details.

Unlock Executive Information

Upgrade to access executive details

Upgrade Now

Find Contacts at 10x Genomics

(Showing 0 of )

Unlock Team Information

Upgrade to access team member details

Upgrade Now

10x Genomics Earnings

This section highlights 10x Genomics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date: April 29, 2025
Time: Before Market
Est. EPS: $-0.46
Status: Unconfirmed

Last Earnings Results

Date: February 12, 2025
EPS: $-0.40
Est. EPS: $-0.29
Revenue: $165.02M

Earnings Call Transcripts

Transcript Quarter Year Date Estimated EPS Actual EPS
Read Transcript Q4 2024 2025-02-12 $-0.29 $-0.40
Read Transcript Q3 2024 2024-10-29 $-0.34 $-0.30
Read Transcript Q2 2024 2024-08-08 $-0.47 $-0.32
Read Transcript Q1 2024 2024-04-30 $-0.46 $-0.50
Read Transcript Q4 2023 2024-02-15 $-0.36 $-0.41
Read Transcript Q3 2023 2023-11-02 $-0.45 $-0.51
Read Transcript Q2 2023 2023-08-03 $-0.39 $-0.53
Read Transcript Q1 2023 2023-05-03 $-0.38 $-0.44

10x Genomics, Inc. (TXG)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Healthcare Medical - Healthcare Information Services

$9.16

Stock Price

$1.12B

Market Cap

1.31K

Employees

Pleasanton, CA

Location

Financial Statements

Access annual & quarterly financial statements for 10x Genomics, including income statements, balance sheets, and cash flow statements..

Annual Income Statement

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Revenue $610.78M $618.73M $516.41M $490.49M $298.85M
Cost of Revenue $196.30M $209.41M $120.39M $74.09M $58.47M
Gross Profit $414.48M $409.31M $396.02M $416.40M $240.38M
Gross Profit Ratio 67.86% 66.20% 76.69% 84.90% 80.44%
Research and Development Expenses $264.70M $270.33M $265.67M $211.75M $123.38M
General and Administrative Expenses $- $340.03M $294.60M $252.86M $200.43M
Selling and Marketing Expenses $- $3.30M $3.70M $4.70M $1.90M
Selling General and Administrative Expenses $344.34M $343.33M $298.30M $257.56M $202.33M
Other Expenses $- $- $-198.00K $-802.00K $1.34M
Operating Expenses $609.04M $674.95M $563.97M $469.31M $325.70M
Cost and Expenses $805.34M $884.36M $684.35M $543.40M $384.17M
Interest Income $18.45M $16.91M $6.65M $206.00K $1.53M
Interest Expense $4.00K $33.00K $476.00K $866.00K $1.68M
Depreciation and Amortization $43.71M $43.62M $33.01M $28.25M $19.02M
EBITDA $-133.99M $-205.11M $-128.49M $-24.59M $-513.77M
EBITDA Ratio -21.94% -33.15% -31.27% -10.91% -27.59%
Operating Income $-194.56M $-194.95M $-167.94M $-52.91M $-85.32M
Operating Income Ratio -31.85% -31.51% -32.52% -10.79% -28.55%
Total Other Income Expenses Net $16.86M $-53.81M $5.97M $-802.00K $-449.15M
Income Before Tax $-177.70M $-248.76M $-161.97M $-53.72M $-534.48M
Income Before Tax Ratio -29.09% -40.21% -31.36% -10.95% -178.85%
Income Tax Expense $4.93M $6.34M $4.03M $4.51M $8.26M
Net Income $-182.63M $-255.10M $-166.00M $-58.22M $-542.73M
Net Income Ratio -29.90% -41.23% -32.15% -11.87% -181.61%
EPS $-1.52 $-2.18 $-1.46 $-0.53 $-5.37
EPS Diluted $-1.52 $-2.18 $-1.46 $-0.53 $-5.37
Weighted Average Shares Outstanding 120.45M 117.17M 113.86M 110.35M 101.15M
Weighted Average Shares Outstanding Diluted 120.45M 117.17M 113.86M 110.35M 101.15M
SEC Filing Source Source Source Source Source


Breakdown December 31, 2024 September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020
Revenue $165.02M $151.65M $153.10M $141.01M $183.98M $153.64M $146.82M $134.28M $156.23M $131.07M $114.61M $114.50M $143.53M $125.30M $115.84M $105.82M $112.22M $71.82M $42.91M $71.91M
Cost of Revenue $54.07M $45.26M $46.21M $45.44M $77.91M $58.12M $47.21M $35.90M $36.83M $30.38M $27.70M $25.48M $27.60M $24.52M $4.92M $17.06M $18.90M $14.41M $10.05M $15.11M
Gross Profit $110.95M $106.39M $106.90M $95.57M $106.06M $95.53M $99.61M $98.39M $119.41M $100.69M $86.91M $89.02M $115.93M $100.78M $110.93M $88.76M $93.32M $57.41M $32.85M $56.80M
Gross Profit Ratio 67.24% 70.20% 69.80% 67.80% 57.70% 62.20% 67.80% 73.30% 76.40% 76.80% 75.80% 77.70% 80.80% 80.40% 95.80% 83.90% 83.16% 79.93% 76.57% 78.99%
Research and Development Expenses $66.97M $66.17M $62.92M $67.94M $55.55M $107.91M $71.46M $67.10M $63.61M $67.29M $70.69M $64.08M $61.88M $54.58M $53.40M $41.88M $39.70M $30.14M $27.54M $25.99M
General and Administrative Expenses $- $- $- $- $82.83M $- $- $- $75.19M $- $- $- $65.18M $- $- $- $54.07M $- $- $-
Selling and Marketing Expenses $- $- $- $- $3.30M $- $- $- $3.70M $- $- $- $4.70M $- $- $- $1.90M $- $- $-
Selling General and Administrative Expenses $93.83M $81.70M $83.04M $84.67M $86.12M $82.42M $91.51M $83.28M $78.89M $73.40M $79.34M $66.67M $69.88M $62.08M $68.70M $56.90M $55.97M $51.55M $44.42M $50.39M
Other Expenses $- $- $-2.68M $-2.35M $3.96M $-1.25M $-1.50M $-1.52M $4.00M $-1.95M $-1.84M $-400.00K $5.00K $-599.00K $521.00K $-729.00K $1.22M $361.00K $-144.00K $-96.00K
Operating Expenses $160.79M $147.88M $148.63M $154.97M $141.68M $190.32M $162.97M $150.38M $142.50M $140.69M $150.02M $130.75M $131.76M $116.66M $122.11M $98.79M $95.68M $81.69M $71.95M $76.38M
Cost and Expenses $214.86M $193.14M $194.84M $200.40M $219.59M $248.44M $210.18M $186.27M $179.33M $171.07M $177.73M $156.23M $159.36M $141.18M $127.02M $115.85M $114.58M $96.10M $82.00M $91.49M
Interest Income $4.03M $4.97M $4.71M $4.74M $4.64M $4.30M $4.10M $3.87M $2.81M $2.02M $1.24M $569.00K $49.00K $49.00K $58.00K $50.00K $61.00K $28.00K $125.00K $1.32M
Interest Expense $- $2.00K $1.00K $1.00K $8.00K $1.00K $5.00K $19.00K $125.00K $114.00K $109.00K $128.00K $217.00K $219.00K $209.00K $221.00K $317.00K $397.00K $306.00K $662.00K
Depreciation and Amortization $10.56M $10.75M $10.90M $11.49M $11.71M $11.42M $11.88M $8.62M $8.47M $8.12M $8.44M $7.97M $7.32M $7.28M $7.19M $6.47M $5.42M $4.88M $4.47M $4.26M
EBITDA $-37.82M $-23.69M $-26.18M $-46.31M $-34.88M $-80.32M $-48.88M $-41.02M $-7.81M $-31.81M $-55.28M $-33.59M $-8.45M $-9.15M $-2.56M $-4.43M $-402.89M $-59.99M $-34.97M $-16.99M
EBITDA Ratio -22.92% -15.62% -20.14% -33.97% -12.99% -59.71% -41.39% -36.96% -10.42% -30.46% -55.60% -36.30% -10.99% -13.11% -9.15% -10.12% -0.96% -33.27% -91.17% -25.53%
Operating Income $-49.84M $-41.48M $-41.74M $-59.40M $-35.61M $-94.80M $-63.36M $-51.99M $-23.10M $-40.00M $-63.12M $-41.73M $-15.83M $-15.88M $-10.33M $-10.22M $-409.58M $-65.25M $-39.42M $-19.88M
Operating Income Ratio -30.20% -27.36% -27.26% -42.12% -19.36% -61.70% -43.15% -38.71% -14.78% -30.51% -55.07% -36.45% -11.03% -12.67% -8.92% -9.65% -364.99% -90.86% -91.88% -27.65%
Total Other Income Expenses Net $1.46M $7.05M $4.66M $1.59M $-10.99M $3.05M $2.59M $2.33M $6.68M $-39.00K $-714.00K $41.00K $-163.00K $-769.00K $370.00K $-900.00K $960.00K $-8.00K $-325.00K $-961.00K
Income Before Tax $-48.38M $-34.44M $-37.08M $-57.80M $-46.60M $-91.74M $-60.77M $-49.65M $-16.41M $-40.03M $-63.83M $-41.69M $-15.99M $-16.65M $-9.96M $-11.12M $-408.62M $-65.26M $-39.74M $-20.84M
Income Before Tax Ratio -29.32% -22.71% -24.22% -40.99% -25.33% -59.71% -41.39% -36.98% -10.50% -30.54% -55.69% -36.42% -11.14% -13.29% -8.60% -10.50% -364.13% -90.87% -92.63% -28.99%
Income Tax Expense $648.00K $1.31M $818.00K $2.15M $2.35M $1.24M $1.65M $1.09M $804.00K $1.88M $627.00K $719.00K $2.46M $523.00K $1.09M $435.00K $6.95M $585.00K $422.00K $298.00K
Net Income $-49.03M $-35.75M $-37.90M $-59.95M $-48.95M $-92.99M $-62.41M $-50.75M $-17.21M $-41.91M $-64.46M $-42.41M $-18.45M $-17.17M $-11.05M $-11.55M $-415.57M $-65.85M $-40.17M $-21.14M
Net Income Ratio -29.71% -23.58% -24.75% -42.52% -26.61% -60.52% -42.51% -37.79% -11.02% -31.98% -56.24% -37.04% -12.85% -13.70% -9.54% -10.92% -370.33% -91.69% -93.62% -29.40%
EPS $-0.41 $-0.30 $-0.32 $-0.50 $-0.41 $-0.79 $-0.53 $-0.44 $-0.15 $-0.37 $-0.57 $-0.38 $-0.16 $-0.15 $-0.10 $-0.11 $-3.87 $-0.65 $-0.41 $-0.22
EPS Diluted $-0.41 $-0.30 $-0.32 $-0.50 $-0.41 $-0.79 $-0.53 $-0.44 $-0.15 $-0.37 $-0.57 $-0.38 $-0.16 $-0.15 $-0.10 $-0.11 $-3.87 $-0.65 $-0.41 $-0.22
Weighted Average Shares Outstanding 120.45M 120.73M 120.07M 119.39M 118.57M 117.73M 116.71M 115.62M 114.76M 114.11M 113.57M 112.97M 111.90M 110.87M 109.87M 108.71M 107.27M 101.34M 98.98M 96.83M
Weighted Average Shares Outstanding Diluted 120.45M 120.73M 120.07M 119.39M 118.57M 117.73M 116.71M 115.62M 114.76M 114.11M 113.57M 112.97M 111.90M 110.87M 109.87M 108.71M 107.39M 101.34M 98.98M 96.83M
SEC Filing Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source

Annual Balance Sheet

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Cash and Cash Equivalents $344.07M $359.28M $219.75M $587.45M $663.60M
Short Term Investments $49.34M $29.41M $210.24M $- $-
Cash and Short Term Investments $393.40M $388.69M $429.98M $587.45M $663.60M
Net Receivables $87.86M $114.83M $104.21M $85.25M $51.21M
Inventory $83.11M $73.71M $81.63M $59.97M $29.96M
Other Current Assets $20.02M $18.79M $19.21M $28.82M $42.62M
Total Current Assets $584.39M $596.02M $635.03M $747.59M $774.37M
Property Plant Equipment Net $309.94M $344.93M $359.21M $230.41M $119.82M
Goodwill $4.51M $4.51M $4.51M $4.51M $-
Intangible Assets $15.67M $16.62M $22.86M $25.40M $22.35M
Goodwill and Intangible Assets $20.18M $21.13M $27.37M $29.91M $22.35M
Long Term Investments $- $- $4.97M $7.60M $8.47M
Tax Assets $- $- $-4.97M $-7.60M $-8.47M
Other Non-Current Assets $4.13M $3.06M $7.37M $10.92M $12.80M
Total Non-Current Assets $334.25M $369.12M $393.94M $271.24M $154.97M
Other Assets $- $- $- $- $-
Total Assets $918.64M $965.14M $1.03B $1.02B $929.34M
Account Payables $12.91M $15.74M $21.60M $17.35M $4.71M
Short Term Debt $9.29M $11.52M $18.07M $10.26M $11.87M
Tax Payables $4.94M $5.05M $4.08M $4.62M $8.65M
Deferred Revenue $20.66M $13.15M $7.87M $5.34M $4.47M
Other Current Liabilities $69.84M $81.70M $79.34M $72.78M $88.42M
Total Current Liabilities $117.63M $127.16M $130.96M $110.36M $118.13M
Long Term Debt $73.33M $83.85M $172.28M $153.69M $114.08M
Deferred Revenue Non-Current $- $8.81M $3.17M $- $-
Deferred Tax Liabilities Non-Current $- $- $-3.17M $- $-
Other Non-Current Liabilities $17.54M $4.28M $-80.00M $-62.79M $-41.94M
Total Non-Current Liabilities $90.87M $96.94M $92.28M $90.90M $72.14M
Other Liabilities $- $- $- $- $-
Total Liabilities $208.50M $224.10M $223.24M $201.26M $190.27M
Preferred Stock $- $- $- $- $-
Common Stock $2.00K $2.00K $2.00K $2.00K $2.00K
Retained Earnings $-1.47B $-1.28B $-1.03B $-863.32M $-805.10M
Accumulated Other Comprehensive Income Loss $-493.00K $-429.00K $-4.33M $22.00K $-50.00K
Other Total Stockholders Equity $2.18B $2.03B $1.84B $1.68B $1.54B
Total Stockholders Equity $710.13M $741.04M $805.74M $817.57M $739.07M
Total Equity $710.13M $741.04M $805.74M $817.57M $739.07M
Total Liabilities and Stockholders Equity $918.64M $965.14M $1.03B $1.02B $929.34M
Minority Interest $- $- $- $- $-
Total Liabilities and Total Equity $918.64M $965.14M $1.03B $1.02B $929.34M
Total Investments $49.34M $29.41M $210.24M $7.60M $8.47M
Total Debt $82.61M $95.37M $95.18M $81.98M $62.98M
Net Debt $-261.45M $-263.91M $-124.57M $-505.47M $-600.62M


Balance Sheet Charts

Breakdown December 31, 2024 September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020
Cash and Cash Equivalents $344.07M $398.16M $379.82M $355.78M $359.28M $311.26M $325.88M $332.32M $219.75M $233.95M $274.19M $312.49M $587.45M $600.44M $621.96M $617.20M $663.60M $768.77M $339.84M $372.43M
Short Term Investments $49.34M $- $269.00K $16.03M $29.41M $45.64M $65.51M $85.97M $210.24M $218.44M $225.55M $226.84M $- $- $- $- $- $- $- $-
Cash and Short Term Investments $393.40M $398.16M $380.09M $371.81M $388.69M $356.91M $391.38M $418.29M $429.98M $452.39M $499.73M $539.32M $587.45M $600.44M $621.96M $617.20M $663.60M $768.77M $339.84M $372.43M
Net Receivables $87.86M $83.53M $91.18M $91.31M $114.83M $103.85M $87.69M $77.94M $104.21M $83.55M $76.20M $76.53M $85.25M $78.43M $59.68M $57.41M $51.21M $36.03M $22.73M $30.85M
Inventory $83.11M $94.05M $88.27M $83.19M $73.71M $80.92M $83.69M $82.31M $81.63M $78.63M $70.65M $63.70M $59.97M $51.14M $44.09M $38.51M $29.96M $25.12M $21.76M $19.36M
Other Current Assets $20.02M $18.16M $19.61M $20.79M $18.79M $20.68M $20.18M $23.36M $19.21M $14.86M $19.65M $35.55M $14.92M $14.09M $31.45M $32.61M $29.60M $70.53M $67.26M $14.19M
Total Current Assets $584.39M $593.89M $579.15M $567.09M $596.02M $562.35M $582.94M $601.89M $635.03M $629.42M $666.23M $697.34M $747.59M $744.10M $757.17M $745.72M $774.37M $900.45M $451.58M $429.73M
Property Plant Equipment Net $309.94M $318.34M $324.16M $332.34M $344.93M $354.20M $355.96M $366.84M $359.21M $328.79M $296.43M $265.88M $230.41M $203.30M $176.45M $163.67M $119.82M $110.49M $99.07M $96.43M
Goodwill $4.51M $4.51M $4.51M $4.51M $4.51M $4.51M $4.51M $4.51M $4.51M $4.51M $4.51M $4.51M $4.51M $4.51M $4.51M $4.51M $- $- $- $-
Intangible Assets $15.67M $16.15M $16.66M $16.13M $16.62M $21.83M $22.29M $22.95M $22.86M $23.49M $24.13M $24.76M $25.40M $26.04M $26.69M $27.34M $22.35M $21.93M $21.55M $-
Goodwill and Intangible Assets $20.18M $20.66M $21.17M $20.64M $21.13M $26.34M $26.80M $27.46M $27.37M $28.00M $28.64M $29.27M $29.91M $4.51M $4.51M $4.51M $22.35M $21.93M $21.55M $-
Long Term Investments $- $- $- $- $- $2.97M $3.47M $4.97M $4.97M $7.09M $7.09M $7.60M $7.60M $8.60M $8.60M $8.60M $- $- $- $-
Tax Assets $- $- $- $- $- $-2.97M $-3.47M $-4.97M $-4.97M $-7.09M $-7.09M $-7.60M $-7.60M $-8.60M $-8.60M $-8.60M $- $- $- $-
Other Non-Current Assets $4.13M $4.90M $5.19M $2.84M $3.06M $5.65M $23.93M $17.83M $7.37M $9.99M $10.29M $10.76M $10.92M $38.65M $39.44M $40.14M $12.80M $9.67M $10.60M $84.22M
Total Non-Current Assets $334.25M $343.90M $350.51M $355.82M $369.12M $386.19M $406.70M $412.14M $393.94M $366.79M $335.36M $305.92M $271.24M $246.47M $220.41M $208.32M $154.97M $142.09M $131.22M $180.65M
Other Assets $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Assets $918.64M $937.79M $929.67M $922.91M $965.14M $948.54M $989.64M $1.01B $1.03B $996.21M $1.00B $1.00B $1.02B $990.57M $977.58M $954.03M $929.34M $1.04B $582.80M $610.38M
Account Payables $12.91M $26.21M $21.25M $20.22M $15.74M $18.84M $23.12M $29.32M $21.60M $21.59M $26.73M $18.96M $17.35M $17.04M $16.18M $15.58M $4.71M $9.49M $9.92M $13.51M
Short Term Debt $9.29M $18.83M $21.64M $11.13M $23.04M $20.01M $18.57M $18.40M $9.04M $16.79M $15.95M $15.27M $5.13M $8.93M $9.81M $12.31M $5.94M $9.95M $7.88M $6.91M
Tax Payables $4.94M $4.29M $5.79M $5.78M $5.05M $3.69M $2.32M $2.30M $4.08M $3.12M $1.45M $1.91M $4.62M $3.30M $4.20M $2.48M $8.65M $1.79M $954.00K $923.00K
Deferred Revenue $20.66M $17.76M $16.44M $14.30M $13.15M $11.14M $9.22M $8.53M $7.87M $6.67M $6.47M $5.43M $5.34M $5.50M $5.27M $4.48M $4.47M $3.77M $3.43M $3.39M
Other Current Liabilities $69.84M $54.14M $45.90M $57.32M $70.18M $51.03M $44.85M $53.46M $88.38M $78.69M $67.31M $52.88M $77.91M $65.61M $77.66M $85.70M $94.36M $120.57M $100.00M $34.34M
Total Current Liabilities $117.63M $121.23M $111.02M $108.73M $127.16M $104.72M $98.09M $112.01M $130.96M $126.86M $117.91M $94.45M $110.36M $100.38M $113.13M $120.55M $118.13M $145.57M $122.18M $59.07M
Long Term Debt $73.33M $76.46M $78.66M $81.05M $167.70M $176.94M $180.66M $185.69M $86.14M $175.67M $182.08M $187.08M $76.85M $151.47M $131.83M $66.34M $57.04M $113.24M $110.46M $112.33M
Deferred Revenue Non-Current $12.51M $12.35M $11.36M $9.79M $8.81M $- $- $- $3.17M $- $- $- $- $- $- $- $- $- $- $-
Deferred Tax Liabilities Non-Current $- $- $- $-9.79M $-1 $- $- $- $-3.17M $- $- $- $- $- $- $- $- $- $- $-
Other Non-Current Liabilities $5.03M $4.95M $4.57M $4.51M $-79.57M $-78.33M $-82.41M $-86.05M $6.14M $-82.11M $-81.91M $-84.96M $14.05M $-61.49M $-51.97M $14.68M $15.10M $-41.34M $-41.10M $29.92M
Total Non-Current Liabilities $90.87M $93.75M $94.59M $95.35M $96.94M $98.61M $98.25M $99.64M $92.28M $93.56M $100.17M $102.12M $90.90M $89.98M $79.87M $81.02M $72.14M $71.89M $69.35M $142.25M
Other Liabilities $- $- $- $- $1 $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities $208.50M $214.99M $205.61M $204.08M $224.10M $203.32M $196.34M $211.65M $223.24M $220.41M $218.07M $196.57M $201.26M $190.35M $192.99M $201.57M $190.27M $217.46M $191.53M $201.32M
Preferred Stock $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Common Stock $2.00K $2.00K $2.00K $2.00K $2.00K $2.00K $2.00K $2.00K $2.00K $2.00K $2.00K $2.00K $2.00K $2.00K $2.00K $2.00K $2.00K $2.00K $2.00K $2.00K
Retained Earnings $-1.47B $-1.42B $-1.38B $-1.34B $-1.28B $-1.24B $-1.14B $-1.08B $-1.03B $-1.01B $-970.19M $-905.73M $-863.32M $-844.87M $-827.70M $-816.65M $-805.10M $-389.52M $-323.68M $-283.51M
Accumulated Other Comprehensive Income Loss $-493.00K $32.00K $-430.00K $-456.00K $-429.00K $-677.00K $-969.00K $-1.48M $-4.33M $-5.49M $-3.96M $-2.44M $22.00K $194.00K $58.00K $48.00K $-50.00K $-52.00K $314.00K $-41.00K
Other Total Stockholders Equity $2.18B $2.14B $2.11B $2.06B $2.03B $1.98B $1.94B $1.88B $1.84B $1.79B $1.76B $1.71B $1.68B $1.64B $1.61B $1.57B $1.54B $1.21B $714.63M $692.62M
Total Stockholders Equity $710.13M $722.80M $724.06M $718.83M $741.04M $745.22M $793.30M $802.38M $805.74M $775.79M $783.52M $806.68M $817.57M $800.22M $784.59M $752.46M $739.07M $825.08M $391.27M $409.07M
Total Equity $710.13M $722.80M $724.06M $718.83M $741.04M $745.22M $793.30M $802.38M $805.74M $775.79M $783.52M $806.68M $817.57M $800.22M $784.59M $752.46M $739.07M $825.08M $391.27M $409.07M
Total Liabilities and Stockholders Equity $918.64M $937.79M $929.67M $922.91M $965.14M $948.54M $989.64M $1.01B $1.03B $996.21M $1.00B $1.00B $1.02B $990.57M $977.58M $954.03M $929.34M $1.04B $582.80M $610.38M
Minority Interest $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities and Total Equity $918.64M $937.79M $929.67M $922.91M $965.14M $948.54M $989.64M $1.01B $1.03B $996.21M $1.00B $1.00B $1.02B $990.57M $977.58M $954.03M $929.34M $1.04B $582.80M $610.38M
Total Investments $49.34M $- $269.00K $16.03M $29.41M $45.64M $65.51M $85.97M $210.24M $218.44M $225.55M $226.84M $7.60M $8.60M $8.60M $8.60M $- $- $- $-
Total Debt $82.61M $85.88M $89.48M $92.18M $95.37M $98.47M $99.62M $102.04M $95.18M $96.23M $99.02M $101.17M $81.98M $80.20M $70.82M $72.50M $62.98M $61.59M $59.17M $59.62M
Net Debt $-261.45M $-312.28M $-290.34M $-263.61M $-263.91M $-212.79M $-226.26M $-230.28M $-124.57M $-137.72M $-175.17M $-211.31M $-505.47M $-520.24M $-551.14M $-544.70M $-600.62M $-707.18M $-280.67M $-312.81M

Annual Cash Flow

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Net Income $-182.63M $-255.10M $-166.00M $-58.22M $-542.73M
Depreciation and Amortization $43.71M $43.62M $33.01M $28.25M $19.02M
Deferred Income Tax $- $- $- $- $1.55M
Stock Based Compensation $140.75M $166.95M $136.85M $95.96M $48.63M
Change in Working Capital $1.25M $17.34M $-39.42M $-87.44M $-50.38M
Accounts Receivables $26.95M $-10.61M $-18.95M $-34.04M $-17.85M
Inventory $-9.78M $7.87M $-21.19M $-30.13M $-14.60M
Accounts Payables $-3.35M $-6.02M $5.86M $11.08M $-7.77M
Other Working Capital $-12.57M $26.10M $-5.13M $-34.36M $-10.16M
Other Non Cash Items $3.58M $11.99M $1.96M $79.00K $306.02M
Net Cash Provided by Operating Activities $6.66M $-15.20M $-33.61M $-21.37M $-217.90M
Investments in Property Plant and Equipment $-12.39M $-48.60M $-131.66M $-101.28M $-38.39M
Acquisitions Net $- $- $-4.00M $-5.45M $-
Purchases of Investments $-48.88M $- $-282.87M $- $-
Sales Maturities of Investments $29.64M $183.02M $67.64M $- $-
Other Investing Activities $-1.00M $-923.00K $-215.23M $- $-1.73M
Net Cash Used for Investing Activities $-32.63M $133.49M $-350.89M $-106.73M $-38.39M
Debt Repayment $- $- $- $- $-37.10M
Common Stock Issued $- $19.48M $21.23M $40.33M $482.27M
Common Stock Repurchased $- $- $- $- $-
Dividends Paid $- $- $- $- $-
Other Financing Activities $10.91M $13.67M $15.82M $35.30M $23.74M
Net Cash Used Provided by Financing Activities $10.91M $13.67M $15.82M $35.30M $468.91M
Effect of Forex Changes on Cash $-164.00K $-33.00K $-44.00K $234.00K $-463.00K
Net Change in Cash $-15.22M $131.93M $-368.72M $-92.57M $212.15M
Cash at End of Period $344.07M $359.28M $227.35M $596.07M $688.64M
Cash at Beginning of Period $359.28M $227.35M $596.07M $688.64M $476.49M
Operating Cash Flow $6.66M $-15.20M $-33.61M $-21.37M $-217.90M
Capital Expenditure $-12.39M $-49.52M $-131.66M $-101.28M $-38.39M
Free Cash Flow $-5.73M $-64.72M $-165.27M $-122.65M $-256.29M

Cash Flow Charts

Breakdown December 31, 2024 September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020
Net Income $-49.03M $-35.75M $-37.90M $-59.95M $-48.95M $-92.99M $-62.41M $-50.75M $-17.21M $-41.91M $-64.46M $-42.41M $-18.45M $-17.17M $-11.05M $-11.55M $-415.57M $-65.85M $-40.17M $-21.14M
Depreciation and Amortization $10.56M $10.75M $10.90M $11.49M $11.71M $11.42M $11.88M $8.62M $8.47M $8.12M $8.44M $7.97M $7.32M $7.28M $7.19M $6.47M $5.42M $4.88M $4.47M $4.26M
Deferred Income Tax $- $- $- $- $23.85M $-26.64M $2.79M $- $- $- $- $- $- $- $- $- $29.00K $- $- $1.52M
Stock Based Compensation $32.54M $33.59M $38.49M $36.13M $38.92M $40.23M $45.70M $42.10M $40.97M $33.51M $36.31M $26.05M $26.90M $25.95M $26.93M $16.18M $14.27M $13.78M $13.86M $6.72M
Change in Working Capital $-1.38M $12.99M $-4.07M $-6.30M $17.07M $16.17M $-9.93M $-5.96M $-19.34M $-9.94M $2.46M $-12.59M $-9.99M $-42.27M $-19.98M $-15.21M $-40.32M $-8.44M $-7.67M $6.05M
Accounts Receivables $-4.37M $7.68M $122.00K $23.52M $-10.97M $-16.16M $-9.75M $26.28M $-20.62M $-7.35M $297.00K $8.73M $-6.83M $-19.39M $-1.64M $-6.19M $-15.19M $-13.30M $8.12M $2.52M
Inventory $9.62M $-4.26M $-5.20M $-9.94M $7.61M $2.57M $-1.86M $-449.00K $-1.43M $-8.66M $-7.37M $-3.74M $-8.78M $-7.13M $-5.60M $-8.61M $-4.75M $-3.36M $-2.40M $-4.09M
Accounts Payables $-13.40M $4.34M $1.12M $4.58M $-3.21M $-4.12M $2.10M $-781.00K $-224.00K $-4.18M $7.39M $2.88M $-1.11M $2.48M $-1.17M $10.88M $-4.46M $-497.00K $-2.16M $-653.00K
Other Working Capital $6.77M $5.23M $-112.00K $-24.46M $23.63M $33.89M $-413.00K $-31.01M $2.93M $10.25M $2.14M $-20.46M $6.73M $-18.22M $-11.57M $-11.29M $-15.91M $8.72M $-11.24M $8.27M
Other Non Cash Items $552.00K $64.00K $64.31M $43.85M $-16.83M $26.50M $463.00K $1.86M $837.00K $660.00K $277.00K $183.00K $13.00K $64.55M $36.00K $30.00K $306.00M $-1.00K $1.00K $17.00K
Net Cash Provided by Operating Activities $-6.75M $21.64M $7.50M $-15.72M $25.76M $-25.30M $-11.53M $-4.12M $13.72M $-9.56M $-16.96M $-20.80M $5.80M $-26.22M $3.12M $-4.08M $-130.18M $-55.63M $-29.52M $-2.58M
Investments in Property Plant and Equipment $-2.72M $-3.89M $-3.88M $-2.91M $-3.45M $-15.44M $-25.36M $-5.28M $-39.73M $-36.57M $-27.22M $-28.14M $-27.62M $-20.23M $-14.57M $-38.87M $-22.27M $-1.31M $-6.74M $-8.08M
Acquisitions Net $- $- $- $- $- $- $- $- $-2.50M $-1.50M $1.50M $1.50M $- $- $- $-5.45M $- $- $- $-
Purchases of Investments $- $- $- $- $- $- $- $- $-1.50M $-11.32M $-29.22M $-242.33M $- $- $- $- $- $- $- $-
Sales Maturities of Investments $- $271.00K $15.82M $13.54M $16.55M $20.34M $20.89M $125.24M $9.06M $16.77M $28.91M $12.91M $- $- $- $- $- $- $- $-
Other Investing Activities $-48.88M $- $-1.00M $13.54M $1 $20.14M $20.89M $124.52M $1.50M $5.44M $-1.50M $-1.50M $- $- $- $- $-927.00K $-801.00K $- $-
Net Cash Used for Investing Activities $-51.59M $-3.62M $11.95M $10.63M $13.10M $4.90M $-4.46M $119.96M $-33.17M $-32.63M $-27.53M $-257.56M $-27.62M $-20.23M $-14.57M $-44.32M $-22.27M $-1.31M $-6.74M $-8.08M
Debt Repayment $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $5.85M $- $- $-31.26M
Common Stock Issued $- $-6.24M $4.60M $1.64M $5.61M $4.37M $7.10M $2.40M $21.23M $2.04M $6.36M $7.83M $40.33M $6.68M $16.19M $8.55M $-780.00K $- $- $-
Common Stock Repurchased $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Dividends Paid $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Financing Activities $4.52M $156.00K $4.60M $1.64M $5.61M $4.37M $7.10M $-5.81M $5.00M $2.04M $6.36M $2.42M $8.90M $6.68M $16.19M $3.52M $2.64M $486.97M $8.05M $-2.56M
Net Cash Used Provided by Financing Activities $4.52M $156.00K $4.60M $1.64M $5.61M $4.37M $7.10M $-3.41M $5.00M $2.04M $6.36M $2.42M $8.90M $6.68M $16.19M $3.52M $7.71M $486.97M $8.05M $-33.82M
Effect of Forex Changes on Cash $-269.00K $156.00K $-3.00K $-48.00K $77.00K $-85.00K $-49.00K $24.00K $251.00K $-85.00K $-192.00K $-18.00K $-82.00K $117.00K $6.00K $193.00K $-319.00K $-21.00K $-7.00K $-116.00K
Net Change in Cash $-54.09M $18.34M $24.04M $-3.50M $47.52M $-15.62M $-8.94M $112.44M $-14.20M $-40.24M $-38.32M $-275.96M $-12.99M $-39.64M $4.75M $-44.69M $-145.05M $430.01M $-28.21M $-44.59M
Cash at End of Period $344.07M $398.16M $379.82M $355.78M $359.28M $311.76M $330.85M $339.79M $227.35M $241.55M $281.79M $320.11M $596.07M $609.07M $648.71M $643.96M $688.64M $833.70M $403.69M $431.90M
Cash at Beginning of Period $398.16M $379.82M $355.78M $359.28M $311.76M $327.38M $339.79M $227.35M $241.55M $281.79M $320.11M $596.07M $609.07M $648.71M $643.96M $688.64M $833.70M $403.69M $431.90M $476.49M
Operating Cash Flow $-6.75M $21.64M $7.50M $-15.72M $25.76M $-25.30M $-11.53M $-4.12M $13.72M $-9.56M $-16.96M $-20.80M $5.80M $-26.22M $3.12M $-4.08M $-130.18M $-55.63M $-29.52M $-2.58M
Capital Expenditure $-2.72M $-3.89M $-3.88M $-2.91M $-3.45M $-15.44M $-25.36M $-5.28M $-39.73M $-36.57M $-27.22M $-28.14M $-27.62M $-20.23M $-14.57M $-38.87M $-22.27M $-1.31M $-6.74M $-8.08M
Free Cash Flow $-9.46M $17.75M $3.62M $-18.64M $22.31M $-40.74M $-36.88M $-9.41M $-26.01M $-46.14M $-44.18M $-48.94M $-21.81M $-46.44M $-11.45M $-42.95M $-152.44M $-56.94M $-36.26M $-10.65M

10x Genomics Dividends

Explore 10x Genomics's dividend history, including dividend yield, payout ratio, and historical payments.

10x Genomics does not currently pay a dividend.

10x Genomics News

Read the latest news about 10x Genomics, including recent articles, headlines, and updates.

Torex Gold Reports First Copper Concentrate Production from Media Luna

Processing plant tie-ins and restart complete; commercial production expected in coming weeks(All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces completion of the four-week tie-in period for the Media Luna Project ("Media Luna") and first production of precious metal-rich copper concentrate. Jody Kuzenko, President and CEO of Torex, stated: "Following almost three years to the day of the release of our feasibility study for the Media Luna Project, we have completed the tie-in period at our processing plant and achieved first production of copper concentrate.

News image

10x Genomics: Lower Cost Innovation May Drive A Rebound

I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption, particularly in the biopharma sector, presenting significant revenue opportunities. Despite historical underperformance and high risk, TXG's leading technologies and potential market penetration justify holding the stock at current price levels.

News image

Torex Gold Reports Year-End 2024 Reserves & Resources

Drilling success continues to support reserve life extensions (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to report year-end 2024 mineral reserves and resources for the Morelos Complex, which includes the producing El Limón Guajes ("ELG") Mine Complex (consisting of the ELG Open Pits and ELG Underground), Media Luna Underground mine, development phase EPO Underground deposit, and surface stockpiles. Table 1: Year-over-year comparison of mineral reserves & mineral resources for the Morelos Complex December 31, 2024 December 31, 2023 Variance Tonnes AuEq AuEq Tonnes AuEq AuEq Tonnes AuEq AuEq (kt) (gpt) (koz) (kt) (gpt) (koz) (kt) (gpt) (koz) Proven & Probable Reserves Media Luna Underground 24,180 4.26 3,311 23,569 4.43 3,360 3% (4%) (1%) ELG Underground 4,019 5.12 662 3,504 5.81 654 15% (12%) 1% EPO Underground 5,029 4.83 781 - - - na na na ELG Open Pit 945 2.69 82 5,553 3.16 565 (83%) (15%) (86%) Surface Stockpiles 6,235 1.30 261 4,972 1.20 192 25% 8% 36% Total Morelos Complex 40,408 3.92 5,096 37,598 3.95 4,771 7% (1%) 7% Measured & Indicated Resources                   Media Luna Underground 29,114 5.07 4,744 27,451 5.23 4,618 6% (3%) 3% ELG Underground 8,451 5.20 1,414 8,176 5.48 1,441 3% (5%) (2%) EPO Underground 7,060 5.18 1,176 6,979 5.14 1,153 1% 1% 2% ELG Open Pit 1,054 2.86 97 6,110 3.13 615 (83%) (9%) (84%) Total Morelos Complex 45,679 5.06 7,431 48,717 5.00 7,828 (6%) 1% (5%) Inferred Resources                   Media Luna Underground 7,675 4.12 1,017 7,330 4.25 1,001 5% (3%) 2% ELG Underground 1,961 4.30 271 2,396 5.28 407 (18%) (19%) (33%) EPO Underground 6,883 4.31 954 4,960 4.52 721 39% (5%) 32% ELG Open Pit 6 3.65 1 399 2.08 27 (98%) 75% (97%) Total Morelos Complex 16,526 4.22 2,243 15,085 4.45 2,156 10% (5%) 4% Notes to Table: 1.

News image

10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products

10x Genomics' ATAC-Seq patents found valid and infringed PLEASANTON, Calif. , March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

News image

Torex Gold Reports Excellent Drill Results from Media Luna West and Initial Results from Media Luna East

Compelling results return multiple high-grade intercepts at both Media Luna East and West (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - February 24, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to provide results from the ongoing drilling program at Media Luna West and results from initial drill testing at Media Luna East. Drilling at both targets supports the Company's exploration strategy, which is focused, in part, on unlocking additional near-mine opportunities at the Media Luna Cluster in order to further enhance and extend the production profile of the Morelos Complex.

News image

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

New single cell and spatial innovations extend 10x Genomics' technology and performanceleadership across all three platforms PLEASANTON, Calif. , Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new product innovations to solidify its position as the best partner for high-performance single cell research at scale.

News image

Torex Gold Reports Q4 and Full Year 2024 Results

2024 marks another solid year of operational and financial results; on track to return to positive free cash flow generation by mid-2025 (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - February 19, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports the Company's financial and operational results for the three months and year ended December 31, 2024. Torex will host a conference call tomorrow morning at 9:00 AM (ET) to discuss the results.

News image

10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

PLEASANTON, Calif. , Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, at 11:10 a.m.

News image

Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties

On Wednesday, 10x Genomics Inc TXG reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of $(0.30).

News image

10x Genomics, Inc. (TXG) Q4 2024 Earnings Call Transcript

10x Genomics, Inc. (NASDAQ:TXG ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Cassie Corneau - Senior Director, IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Adam Taich - CFO Conference Call Participants Dan Brennan - TD Cowen Patrick Donnelly - Citi Dan Arias - Stifel Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Tejas Savant - Morgan Stanley Dan Leonard - UBS Subbu Nambi - Guggenheim Securities Kyle Mikson - Canaccord Genuity Luke Sergott - Barclays Matt Larew - William Blair Matt Sykes - Goldman Sachs Michael Ryskin - Bank of America Operator Thank you for standing by. My name is [Prilla] and I will be your conference operator today.

News image

Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings

The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

News image

10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates

10x Genomics (TXG) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.41 per share a year ago.

News image

10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

PLEASANTON, Calif. , Feb. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for 2025.

News image

Seeking Clues to 10x Genomics (TXG) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for 10x Genomics (TXG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

News image

Cathie Wood dumped Palantir to buy these biotech stocks

Ark Invest Management chief executive officer (CEO) Cathie Wood is a lauded yet controversial figure.

News image

Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology

Landmark single-cell dataset of one billion cells will be used to train new AI models to advance researchers' understanding of cellular behavior and gene function REDWOOD CITY, Calif. , Feb. 6, 2025 /PRNewswire/ -- Today, the Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, an effort to generate an unprecedented one billion cell dataset to fuel rapid progress in AI model development in biology.

News image

10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News image

Torex Gold Provides Q4 2024 Update on Media Luna Project

Construction substantially complete and first copper concentrate on track for March (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) provides a Q4 2024 update on the development of its Media Luna Project ("Media Luna"). Unless otherwise stated, progress and milestones referenced in this press release are as of December 31, 2024.

News image

Cathie Wood's Top Biotech Plays for February

Don't look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns.

News image

Spatial Omics Research Report 2023-2034: Market to reach $1.09 Billion - 10x Genomics Enhances Spatial OMICS with New Visium Spatial Gene Expression for FFPE

Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Spatial Omics Market by Technology, by Product, by Workflow, by Sample Type, by End-user, and by Region" report has been added to ResearchAndMarkets.com's offering. The global spatial OMICS market accounted for USD 0.372 billion in 2023 and is expected to reach USD 1.09 billion by 2034 with a CAGR of 10.27% during the forecast period 2024-2034

News image

10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

PLEASANTON, Calif. , Jan. 28, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Wednesday, February 12, 2025.

News image

Torex Gold Provides 2025 Operational Guidance and Updated Five-Year Production Outlook

On track to return to positive free cash flow mid-year as Media Luna ramps up (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - January 14, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) provides 2025 operational guidance as well as an updated five-year production outlook for the Morelos Complex. Full-year guidance assumes a four-week shutdown of the processing plant during the first quarter to carry out upgrades and tie-ins required to complete the Media Luna Project.

News image

Torex Gold Delivers on Full-Year Production Guidance

2024 marks the sixth consecutive year production guidance has been achieved Toronto, Ontario--(Newsfile Corp. - January 8, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports fourth quarter gold production of 103,795 ounces ("oz") and full-year gold production of 452,523 oz, within the Company's revised guidance range of 450,000 to 470,000 oz (original guidance of 400,000 to 450,000 oz). Fourth quarter and full-year gold sold were 108,647 oz and 455,932 oz, respectively.

News image

10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PLEASANTON, Calif. , Jan. 2, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present at the 43rd Annual J.P.

News image

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Even the perpetually moving Cathie Wood takes a step back over the holidays. The co-founder, CEO, and investment manager for Ark Invest has been slowing the pace of her portfolio moves lately.

News image

U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products

PLEASANTON, Calif. , Dec. 23, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S. District Court for the District of Delaware against the GeoMx products sold by Bruker Corporation (Nasdaq: BRKR), which acquired the product line from NanoString Technologies.

News image

Torex Gold to Restart Operations and Project Activities at the Morelos Complex

Toronto, Ontario--(Newsfile Corp. - December 17, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports that the Director General of Mines under the Federal Ministry of Economy has lifted the temporary suspension notice and allowed for all activities within the Morelos Complex to resume. Jody Kuzenko, President & CEO of Torex, stated: "Following notification that the temporary suspension has been lifted by the Director General of Mines, all production and development activities at the Morelos Complex will resume, including open pit and underground mining, processing operations, and all activities associated with the Media Luna Project.

News image

Torex Gold Receives Notice of Temporary Suspension from the Ministry of Economy

Toronto, Ontario--(Newsfile Corp. - December 9, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports that the Company has received a notification from the Director General of Mines under the Federal Ministry of Economy that all activities within the Morelos Property are to be temporarily suspended to support their inspection associated with the fatal incident at the El Limón Guajes underground mine ("ELG Underground") on December 5th. As a result, all operational and project activities within the Morelos Complex have been temporarily halted pending permission from officials to resume activities.

News image

Torex Gold Provides an Update on the Fatalities at ELG Underground

Toronto, Ontario--(Newsfile Corp. - December 9, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) provides an update on the carbon monoxide exposure at the El Limón Guajes underground mine ("ELG Underground") that claimed the lives of two employees and one contractor and injured a second contractor. The relevant authorities have all been notified and the Company is fully cooperating with regulators.

News image

Torex Gold Reports Three Fatalities at the ELG Underground Mine

Toronto, Ontario--(Newsfile Corp. - December 5, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) regretfully announces that during the day shift on December 5th, a fatal carbon monoxide gas exposure occurred, which claimed the lives of two employees and one contractor at the El Limón Guajes underground mine ("ELG Underground"). A fourth contract employee was also in the area and is currently in hospital and expected to recover.

News image

Similar Companies

B
Beam Therapeutics Inc.

BEAM

Price: $22.21

Market Cap: $2.22B

F
Fate Therapeutics, Inc.

FATE

Price: $0.85

Market Cap: $97.33M

G
Guardant Health, Inc.

GH

Price: $43.14

Market Cap: $5.32B

T
Twist Bioscience Corporation

TWST

Price: $40.36

Market Cap: $2.41B

V
Veracyte, Inc.

VCYT

Price: $30.12

Market Cap: $2.35B

Related Metrics

Explore detailed financial metrics and analysis for TXG.